识别特异性蛋白4的自身抗体与抗转录中介因子1共存,并与幼年型肌炎的独特临床特征和免疫遗传风险因素相关
在336例幼年型肌炎和91例健康对照中,用酶联免疫吸附法检测抗Sp4自身抗体,23例(7%)患者阳性而对照均阴性;抗Sp4阳性者抗TIF1抗体阳性率显著更高(21例[91%] vs 92例[30%],P < 0.001),在抗TIF1阳性亚组中雷诺现象更常见且天冬氨酸氨基转移酶峰值更低,白种患者中DQA1*04和DRB1*08与抗Sp4相关。
要点
- 抗Sp4自身抗体见于7%(23/336)幼年型肌炎患者,健康对照均阴性。
- 抗Sp4阳性者抗TIF1抗体阳性率91%(21例),显著高于阴性者的30%(92例)。
- 抗TIF1阳性亚组中,抗Sp4阳性者雷诺现象更常见(38% vs 2%),天冬氨酸氨基转移酶峰值更低。
核心结论
- 抗Sp4自身抗体见于幼年型特发性炎症性肌炎患者,主要与抗TIF1自身抗体共存。
- 抗Sp4阳性患者构成抗TIF1阳性肌炎的一个表型亚群,以频繁雷诺现象和肌肉受累较轻为特征,与成人相应抗体阳性者相似。
- 在白种幼年型特发性炎症性肌炎患者中识别出抗Sp4相关的新的免疫遗传风险因素。
研究设计与样本
- 横断面队列研究,纳入336例幼年型肌炎患者和91例健康对照,采用酶联免疫吸附法检测血清抗Sp4自身抗体。
- 比较有无抗Sp4自身抗体患者的临床特征、结局和HLA等位基因。
主要发现
- 抗Sp4自身抗体见于23例(7%)幼年型肌炎患者,91例健康对照均未检出。
- 抗Sp4自身抗体在各临床肌炎亚组中均有发现。
- 抗Sp4阳性者抗TIF1抗体阳性频率显著更高(21例[91%] vs 92例[30%],P < 0.001)。
- 在抗TIF1抗体阳性亚组中,抗Sp4阳性者雷诺现象更常见(8例[38%] vs 2例[2%],P < 0.001),且天冬氨酸氨基转移酶峰值显著更低。
- 抗Sp4阳性患者中无一例需要轮椅。
关键数值与推荐
- 抗Sp4自身抗体阳性率:幼年型肌炎患者23例(7%),健康对照0例。
- 抗TIF1抗体阳性率:抗Sp4阳性组21例(91%) vs 抗Sp4阴性组92例(30%),P < 0.001。
- 抗TIF1阳性亚组中雷诺现象:抗Sp4阳性组8例(38%) vs 抗Sp4阴性组2例(2%),P < 0.001。
- 抗TIF1阳性亚组中天冬氨酸氨基转移酶峰值在抗Sp4阳性者显著更低。
- 白种患者中DQA1*04和DRB1*08与抗Sp4自身抗体相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Autoantibodies recognizing specificity protein 4 (Sp4) were recently discovered in adults with idiopathic inflammatory myopathies (IIM). Anti-Sp4 autoantibodies co-occurred in patients with anti-transcription intermediary factor 1 (anti-TIF1) autoantibody-positive dermatomyositis (DM) and were associated with a reduced risk of cancer. In the present study, the prevalence and clinical features associated with anti-Sp4 autoantibodies in juvenile-onset IIM were investigated. METHODS: Serum samples from 336 patients with juvenile myositis in a cross-sectional cohort and 91 healthy controls were screened for anti-Sp4 autoantibodies using enzyme-linked immunosorbent assay. Clinical characteristics, outcomes, and HLA alleles of those with and those without anti-Sp4 autoantibodies were compared. RESULTS: Anti-Sp4 autoantibodies were present in 23 patients (7%) with juvenile myositis and were not present in any of the controls. Anti-Sp4 autoantibodies were found among each clinical myositis subgroup. The frequency of TIF1 autoantibody positivity was significantly higher among those with anti-Sp4 autoantibodies (21 [91%] versus 92 [30%], P < 0.001). In the anti-TIF1 autoantibody-positive subgroup, Raynaud's phenomenon (8 [38%] versus 2 [2%], P < 0.001) was more common and peak aspartate aminotransferase was significantly lower in those with anti-Sp4 autoantibodies. None of the patients with anti-Sp4 autoantibodies required a wheelchair. Among White patients, DQA1*04 and DRB1*08 were associated with anti-Sp4 autoantibodies. CONCLUSION: Anti-Sp4 autoantibodies were found in patients with juvenile-onset IIM, predominantly those with coexisting anti-TIF1 autoantibodies. Patients with anti-Sp4 autoantibodies represent a phenotypic subset of anti-TIF1 autoantibody-positive myositis characterized by frequent Raynaud's phenomenon and less pronounced muscle involvement, similar to adults with these autoantibodies. Novel immunogenetic risk factors for White patients with IIM were identified among juveniles with anti-Sp4 autoantibodies.
引用
- Sherman MA, Pak K, Pinal-Fernandez I, et al. Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis. Arthritis Rheumatol. 2023. PMID: 36996276. doi:10.1002/art.42512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。